Iradimed (IRMD) Research & Development (2013 - 2026)

Iradimed (IRMD) has reported Research & Development for 14 consecutive years, with $4.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 5.89% year-over-year to $4.2 million in Q2 2026; TTM through Jun 2026 was $17.5 million, a 6.27% increase from a year earlier, with the FY2025 full-year figure at $17.4 million, up 11.55% from the prior year.
• Research & Development was $4.2 million for Q2 2026 at Iradimed, up from $4.1 million in the prior quarter.
• Over five years, Research & Development peaked at $4.6 million in Q3 2025 and troughed at $2.9 million in Q3 2023.
• A 5-year average of $3.7 million and a median of $3.7 million in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development fell 9.16% in 2023 and soared 35.68% in 2024, its largest moves.
• Over 5 years, Research & Development stood at $3.7 million in 2022, then dropped by 9.16% to $3.3 million in 2023, then soared by 35.68% to $4.5 million in 2024, then gained by 1.91% to $4.6 million in 2025, then slipped by 7.77% to $4.2 million in 2026.
• The last three Research & Development figures came in at $4.2 million (Q2 2026), $4.1 million (Q1 2026), and $4.6 million (Q4 2025), per Business Quant data.